Tempest TherapeuticsTPST
About: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Employees: 17
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1.1% more ownership
Funds ownership: 8.57% [Q1] → 9.66% (+1.1%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
12% less call options, than puts
Call options by funds: $185K | Put options by funds: $210K
20% less funds holding
Funds holding: 30 [Q1] → 24 (-6) [Q2]
37% less capital invested
Capital invested by funds: $7.43M [Q1] → $4.7M (-$2.73M) [Q2]
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 81 / 221 met price target | 4,463%upside $47 | Buy Reiterated | 10 Oct 2024 |
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 81 / 221 met price target | 4,463%upside $47 | Buy Reiterated | 15 Aug 2024 |
